GIC-backed Asia Healthcare Holdings weighs IPO amid market uncertainty

A Singapore-backed Indian private healthcare investment group is considering a stock exchange listing within the next 12 to 18 months, though market volatility remains a key concern for its leadership.

According to a report by The Star, Asia Healthcare Holdings (AHH), which is backed by Singapore's GIC and TPG and has invested more than $300 million (€252 million) in healthcare businesses over the past decade, is monitoring market conditions closely before committing to a listing. Executive Chairman Vishal Bali told Reuters that a final decision would depend on market stability.

Bali said: "We believe an IPO is the right trajectory for AHH over the next year to 18 months, but it all depends on the market stability. With the current bloodbath, one should not even think about it."

AHH invests in and scales single-specialty healthcare companies, and is actively exploring opportunities in gastroenterology and pathology diagnostics as part of its next growth phase. The company currently generates approximately 400 million rupees (€4.4 million) worth of pathology work through its hospital network.

India's pathology laboratory services market, valued at roughly $19.5 billion (€16.4 billion) in 2025, is projected to more than double to $45 billion (€37.8 billion) by 2034, growing at an annual rate of 9%, according to market research firm IMARC Group.

AHH has previously acquired and scaled businesses including Motherhood Hospitals, Nova IVF, and the Asian Institute of Nephrology and Urology, and now plans to extend these services into Tier-2 and Tier-3 cities. The company is not considering individual exits from its portfolio companies.

Bali confirmed AHH does not require additional capital but could deploy up to $150 million (€126 million) over the next two years, with investments contingent on identifying a new vertical.

Uncover the full details of AHH's growth strategy and IPO outlook in the full article.